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Living donor liver resections are associated with significant postoperative pain. Epidural analgesia is the gold standard for 
postoperative pain management, although it is often refused or contraindicated. Surgically placed abdominal wall catheters 
(AWCs) are a novel pain modality that can potentially provide pain relief for those patients who are unable to receive an epidu-
ral. A retrospective review was performed at a single center. Patients were categorized according to their postoperative pain 
modality: intravenous (IV) patient-controlled analgesia (PCA), AWCs with IV PCA, or patient-controlled epidural analgesia 
(PCEA). Pain scores, opioid consumption, and outcomes were compared for the first 3 postoperative days. Propensity score 
matches (PSMs) were performed to adjust for covariates and to confirm the primary analysis. The AWC group had signifi-
cantly lower mean morphine-equivalent consumption on postoperative day 3 [18.1 mg, standard error (SE) 5 3.1 versus 28.2 
mg, SE 5 3.0; P 5 0.02] and mean cumulative morphine-equivalent consumption (97.2 mg, SE 5 7.2 versus 121.0 mg, SE 
5 9.1; P 5 0.04) in comparison with the IV PCA group; the difference in cumulative-morphine equivalent remained significant 
in the PSMs. AWC pain scores were higher than those in the PCEA group and were similar to the those in the IV PCA group. 
The AWC group had a lower incidence of pruritus and a shorter hospital stay in comparison with the PCEA group and had a 
lower incidence of sedation in comparison with both groups. Time to ambulation, nausea, and vomiting were comparable 
among all 3 groups. The PSMs confirmed all results except for a decrease in the length of stay in comparison with PCEA. 
AWCs may be an alternative to epidural analgesia after living donor liver resections. Randomized trials are needed to verify the 
benefits of AWCs, including the safety and adverse effects. 
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Liver transplantation is the only option for survival for
patients dying from end-stage liver disease.1
Unfortunately, eligible transplant organs from deceased
donors are scarce, and approximately 5% to 10% of
patients waiting for a liver transplant will die without
receiving a donation.2 Living liver donor transplantation
(LLDT) programs have become a critical resource for
those waiting for a lifesaving transplant.
Living donors are relatively healthy individuals who
voluntarily provide a portion of their liver to a recipi-
ent. Donors have no medical indication for surgery
and gain no procedural benefit from a hepatectomy.
These patients voluntarily expose themselves to a life-
threatening procedure that is associated with a high
rate of complications.3,4 Efforts to improve the safety
and perioperative care of living liver donors are
needed to ensure the viability of LLDT programs—
future donors may be dissuaded by the risk of
morbidity and mortality.5
Postoperative pain is a significant source of morbid-
ity after liver surgery.6 This is due to the large subcos-
tal incisions that are required for surgical exposure.
Approximately 63% of liver donors report more pain
than anticipated after surgery.5 Although epidural
analgesia is considered the gold standard to manage
postoperative pain after major abdominal surgeries
and has been found to be superior to intravenous (IV)
patient-controlled analgesia (PCA),7-9 epidural use is
associated with rare but significant adverse complica-
tions, such as epidural and spinal hematomas.
Although no cases of spinal or epidural hematomas
have been reported after LLDT, theoretically, there is
an increased risk of this complication due to altera-
tions in the coagulation profile after liver surgery.10,11
Thus, because of a theoretically increased risk, clini-
cians may be reluctant to place epidural catheters for
living donor liver resection patients.
An alternative to epidural analgesia is increased IV
opioid use. Opioids are effective for pain at rest; how-
ever, higher doses are required for movement-related
pain.12 Furthermore, they are associated with side
effects such as nausea, vomiting, sedation, and respi-
ratory depression.13 Although IV lidocaine infusions
have been shown to be effective for postoperative pain
management in abdominal surgeries, their use in liver
surgery is limited because of an increased potential
for toxicity.14
An injection of local anesthetics within the transver-
sus abdominis plane (TAP), known as the TAP block,
has been shown to be an effective analgesic interven-
tion in a variety of abdominal surgeries.15-17 A cathe-
ter placed along this plane and used for repeated
bolus administration has been assessed in several
small studies and case series.16,18-20 Previous studies
used small sample sizes and often lacked a control
group; this limited their ability to inform on the wide-
spread use of this intervention.
Unlike TAP catheters placed with anatomical land-
marks or ultrasound-guidance, LLDT catheters can
be placed under direct vision at the end of the surgery
so they can be located closer to the nociceptive pain
fibers, and this may be associated with a lower rate of
catheter failure. To avoid confusion, we refer to surgi-
cally placed TAP catheters as abdominal wall cathe-
ters (AWCs). These catheters are also identified as
medial open transversus abdominal plane catheters
in the literature.21 The primary aim of this study was
to retrospectively compare the effects of AWCs after
LLDT to the 2 standard postoperative pain modalities,
IV PCA and patient-controlled epidural analgesia
(PCEA), on postoperative pain scores and opioid
consumption during the 3 postoperative days after
surgery. Secondary aims of this study were to deter-
mine whether there are differences with respect to
in-hospital recovery milestones and adverse events.
PATIENTS AND METHODS
This retrospective study was reviewed and approved by
the research ethics board at the Toronto General
Hospital (Toronto, Canada). Between April 2004 and
December 2011, 340 consecutive patients who had
undergone elective right lobe donor hepatectomy surgery
were identified from institutional electronic databases.
For patients undergoing orthotopic liver transplantation,
AWCs were first used at our institution in April 2010
because of the surgeon’s preference to reduce the hypo-
tension associated with epidural analgesia after surgery.
Preoperative Assessment
All patients received a consultation with a liver trans-
plant surgeon to determine eligibility and appropriate-
ness for becoming a liver donor. Eligible patients
subsequently underwent standardized assessments in
the preoperative anesthesia consultation clinic. At
this visit, information was provided regarding the
postoperative pain intensity associated with an upper
abdominal incision and the various pain modalities
available, such as IV PCA, PCEA, and AWCs (if AWCs
were available at the time). Known risks and benefits
associated with each pain modality were discussed.
All patients were informed that AWCs had not been
formally studied but had a high safety profile in local
quality assessment studies. We also disclosed poten-
tial risks such as catheter failure, infection, bleeding,
and complications related to local anesthetic toxicity,
such as blurry vision, dizziness, light-headedness,
seizure, and cardiac failure.
Intraoperative and Postoperative Management
On the day of surgery, patients who consented to
PCEA analgesia were brought into the operating room
and placed in a sitting position on the operating room
table. The standard site of epidural placement for this
type of surgery ranged from thoracic spine level T7 to
T10. After the placement of a flexible epidural cathe-
ter, placement was confirmed with a 3-mL test dose of
2% lidocaine.
All patients were attached to standard Canadian
Anesthesiology Society monitors before the induction
of anesthesia. Anesthesia was induced with fentanyl,
propofol, and a nondepolarizing muscle relaxant at
doses deemed appropriate by the attending anesthesi-
ologist. Upon the induction of anesthesia, an arterial
cannula was placed in the radial artery for invasive
blood pressure monitoring, and central venous access
was obtained for central venous pressure monitoring.
General anesthesia was maintained with a volatile
anesthetic agent, and the goal was to keep the central
venous pressure between 2 and 6 mm Hg. If a thoracic
epidural had been placed, local anesthetic infusions
were typically started intraoperatively. Epidurals were
infused with a solution of 0.1% bupivacaine with
0.015 mg/mL of hydromorphone. Infusions were deliv-
ered with an Abbott GemStar infusion pump (Hospira,
Lake Forest, IL) at a rate of 5 mL/hour. Patients were
given intraoperative IV opioids at the discretion of the
attending anesthesiologist.
Patients included in this study underwent elective
right lobe donor hepatectomy surgery. All surgeries
used a right subcostal oblique incision. The surgical
technique was similar across different types of sur-
geons. Surgeons dissected out muscles of the anterior
abdominal wall during surgical closure of the subcos-
tal incision in patients receiving an AWC. They identi-
fied the plane between the internal oblique and
transversus abdominis muscle, which is the TAP. A
Tuohy needle was used to create 2 new insertions
through the skin, and 2 multibore catheters (Portex
epidural catheters, Smiths Medical, Markham,
Canada) were placed along this plane deep into the
fascial layer. One catheter was positioned medially in
close proximity to the rectus sheath, and the other
was placed in the right intercostal area. Catheters
were placed to approximately cover the T7 to T11
intercostal nerve supply. The wound was then closed,
with the 2 ends of the catheters secured in place with
sterile dressings. A bolus of 0.125% bupivacaine (0.2
mL/kg) per catheter at the end of the operative case,
before anesthesia emergence, was given at the discre-
tion of the surgeon and the attending anesthesiologist.
Patients were extubated in the operating room post-
operatively and were taken to the postanesthesia care
unit. Patients in the IV PCA and AWC groups received
a hand-held pendant connected to the IV PCA pump,
whereas those in the PCEA group received a hand-
held pendant for an epidural infusion pump. There
were standardized institutional protocols for those
receiving IV PCA, PCEA, or AWCs postoperatively. The
IV PCA protocol used either morphine (1 mg/mL) or
hydromorphone (0.4 mg/mL). The IV PCA pumps
were set to deliver a dose of 1 to 2 mg of morphine
with a 5-minute lockout period and a 4-hour maxi-
mum dose of 40 mg or 0.2 to 0.4 mg of hydromor-
phone with a 5-minute lockout period and a 4-hour
maximum dose of 10 mg. Patients in the PCEA group
received a 0.1% bupivacaine solution with 0.015 mg/mL
of hydromorphone at an infusion rate of 5 mL/hour
with a 3-mL bolus, a 20-minute lockout period, and a
4-hour maximum of 50 mL. Patients in the AWC group
received a bolus of 0.125% bupivacaine (0.2 mL/kg) per
catheter twice a day in addition to IV PCA as described
previously. All patients were followed by the liver trans-
plant team and the acute pain service (APS) postopera-
tively. The APS team visited each patient daily and
modified the infusion/bolus protocol if pain control was
not satisfactory or if adverse effects were significant.
PCA, PCEA, and AWCs were removed when acute pain
was minimal as determined by the APS team. Patients
were then transferred to a breakthrough parental or oral
opioid regimen. Most patients received oral acetamino-
phen every 6 hours when they were able to tolerate fluid
sips.
Data were collected retrospectively after patients
had been discharged from hospital. We used institu-
tional databases of scanned electronic charts and
archived APS records to retrieve data on each patient,
including the following: postoperative pain modality;
type and dose of intraoperative opioids, dexametha-
sone, and ketamine; intraoperative blood loss, fluid
intake, and length of procedure; postoperative pain
intensity as measured by a numeric rating scale (11-
point scale, with 0 indicating no pain and 10 indicat-
ing the worst possible pain) every 6 hours; daily IV
opioid consumption in morphine equivalents (a con-
version of 1:5 was used to convert hydromorphone to
morphine)22; adverse effects (ie, nausea, vomiting,
sedation, or pruritus); time to fluid sips and full diet;
time to ambulation; and length of hospital stay.
Outcomes were collected for the first 3 days after
surgery.
Intraoperative opioids were separated into short-
and long-acting opioids; long-acting opioids such as
hydromorphone and morphine were combined to give
a total intraoperative morphine-equivalent dose per
patient, and fentanyl was recorded as a short-acting
opioid. Sedation, nausea, vomiting, and pruritus were
assessed by the attending step-down or intermediate-
care nurse every 6 hours. Sedation was assessed with
a 4-point scale: (0) alert, (1) mildly drowsy but easy to
arouse, (2) moderately drowsy but easy to arouse, and
(3) somnolent and difficult to arouse. If increased
sedation became troublesome for patients in the
PCEA group (sedation score of 3 for 2 days), the epi-
dural solution was then changed to 0.2% ropivacaine
without any opioids. If pruritus became troublesome
for patients in any group, patients were treated with
either 25 mg of diphenhydramine or 25 mg of hydrox-
yzine orally. If patients in the PCEA group required
2 or more doses of antipruritic medications, their
epidural solutions were changed to 0.2% ropivacaine.
Demographic information, including sex, age,
height, weight, surgeon, and date of surgery, were
also obtained from the electronic medical records. The
anesthetic record, APS notes, and progress notes were
screened to determine whether a patient had a func-
tioning or nonfunctioning epidural or AWCs. If a note
described a malfunctioning (ie, leaking) or nonfunc-
tioning epidural (ie, no pain relief with bolus medica-
tion) or AWCs that were not replaced, the patient was
excluded from the study. If a malfunctioning or non-
functioning catheter was removed and a new one was
reinserted (ie, removing and replacing an epidural
catheter or inserting new AWCs with anatomical land-
marks/ultrasound guidance), the patient was classi-
fied according to the original group assignment.
Crossovers (ie, patients started with IV PCA and sub-
sequently switched to an epidural) were also excluded
from this retrospective study. Furthermore, patients
who received only 1 AWC were excluded.
Statistical Analysis
An analysis of postoperative outcomes was conducted
on the basis of patients’ postoperative pain modalities.
The daily morphine-equivalent opioid consumption
analysis was restricted to the IV PCA and AWC groups
because those with well-functioning PCEAs invariably
received substantially less opioids. A mixed-design
analysis of variance (ANOVA) was used to assess the
effect of pain modality on opioid use and the interac-
tion between postoperative opioid consumption and
time after surgery. Postoperative days 0, 1, 2, and 3
were used as time points in this analysis. The data
were tested for normality, and a log transformation
was applied when necessary. Sedation scores were
collapsed into a binary outcome where a score > 1
indicated the presence of sedation and a score of 0 or
1 indicated its absence—this was to assess for an
impact on clinically important sedation. A chi-square
test was applied to determine differences between
groups for categorical variables (sex, intraoperative
ketamine or dexamethasone, nausea, vomiting, pruri-
tus, and sedation), and a t test for ANOVA was applied
for the continuous variables [age, body mass index
(BMI), intraoperative opioids, intraoperative fluids and
blood loss, length of procedure, time to fluids and full
diet, time to ambulation, and length of hospital stay].
The area under the pain curve (AUPC) for each group
was calculated for 2 time periods: pain scores from
postoperative day 0 at 1800 hours to postoperative
day 1 at 2400 hours (time 1) and pain scores from
postoperative day 1 at 2400 hours to postoperative
day 3 at 0600 hours (time 2). Patients were excluded
from the AUPC if they had 3 or more missing data
points and if they had 2 consecutive missing pain
level data points. The AUPC analysis was conducted
with a nonparametric method.
A propensity score analysis was conducted to adjust
for covariates and to confirm the primary analysis.
The first step of the planned propensity score analysis
was the estimation of the probability of receiving the
treatment of interest (ie, IV PCA, PCEA, or AWC). An
estimation of this probability was calculated with logis-
tic regression modeling, which included the following
baseline variables: age, sex, weight, height, intraopera-
tive fentanyl, intraoperative morphine equivalence,
intraoperative dexamethasone, intraoperative ketamine,
surgeon, fluid intake, estimated blood loss, and length
of the procedure. Propensity matching was performed
with the nearest neighbor matching method with a cali-
per of 20% of the pooled standard deviation of the logit
of the propensity score. Two propensity matches,
matching patients in the AWC group to the IV PCA
group and matching patients in the AWC and PCEA
groups, were performed. No replacements in the match-
ing were performed, and if patients in the non-AWC
group were not matched to a patient in the AWC group,
they were excluded from the matched populations.
Analyses were conducted with SPSS 20 (SPSS, Inc.,
Chicago, IL), and the propensity score match (PSM)
and the analysis were performed with R Statistical
Software 3.1.1 (R Foundation, Vienna, Austria). All
tests used a level of significance of a 5 0.05.
RESULTS
Sample Size, Clinical Characteristics, and PSM
A total of 340 patients were eligible for inclusion in
this study. After the exclusion of nonfunctioning/mal-
functioning epidurals or AWCs and crossovers, there
were 167 patients in the IV PCA group, 68 patients in
the PCEA group, and 84 patients in the AWC group.
The exclusions included 21 patients in the AWC group
who were excluded because of the placement of only 1
AWC,19 which was nonfunctioning and not replaced.2
Two epidurals were nonfunctioning but were later
replaced, so those patients remained in the analysis.
Age, sex, BMI, intraoperative ketamine use, estimated
blood loss, and length of procedure were similar across
the 3 groups (Table 1). The PCEA group received fewer
intraoperative morphine equivalents than the IV PCA
and AWC groups. This was most likely due to intraoper-
ative analgesia provided by epidural use. The IV PCA
group received more intraoperative fentanyl, which may
have been related to increased pain upon anesthetic
emergence because those in the AWC group may have
received a bolus of local anesthetics before extubation.
Furthermore, more patients in the AWC group received
intraoperative dexamethasone in comparison with the
other groups. At our institution, dexamethasone is given
as prophylaxis for postoperative nausea and vomiting
(PONV), and more patients in the AWC group may have
been at high risk for PONVand needed prophylaxis.
Two PSMs were performed, with adjustments for
baseline covariates. Eighty-three patients in the AWC
group were matched to 83 patients in the IV PCA
group, whereas 26 patients in the AWC group were
matched to 26 patients in the PCEA group.
Opioid Consumption
Figure 1 depicts the daily mean postoperative morphine-
equivalent opioid consumption for the IV PCA and AWC
groups. Mean morphine-equivalent opioid consumption
was significantly lower in the AWC group [18.1 mg,
standard error (SE) 5 3.1 mg] on day 3 versus the IV
PCA group (28.2 mg, SE 5 3.0 mg). Mean cumulative
morphine-equivalent opioid consumption was also lower
in the AWC group (97.2 mg, SE 5 7.2 mg) versus the IV
PCA group (121.0 mg, SE 5 9.1 mg). The mixed-design
ANOVA with log-adjusted opioid consumption data indi-
cated an interaction between postoperative time and
morphine-equivalent opioid consumption for patients in
the AWC group. PSMs demonstrated similar differences
in morphine-equivalent opioid consumption in the
unmatched data for all days; however, there was a loss
of significance in the difference in the postoperative day
3 consumption (AWC, 16.6 mg, SE 5 2.7 mg versus IV
PCA, 23.8 mg, SE 5 3.7 mg; P 5 0.135). The difference
in cumulative morphine-equivalent opioid consumption
remained significant in the propensity-matched data
(AWC, 98.0 mg, SE 5 7.4 mg versus IV PCA, 136.1 mg,
SE 5 17.0 mg; P 5 0.04).
Pain Scores
Figure 2 depicts the pain scores for each group during
the first 3 postoperative days. The AUPC analysis
included 197 patients (88 IV PCA patients, 46 PCEA
patients, and 63 AWC patients); 122 patients were
excluded because of a priori conditions. The AUPC
was not significantly different in patients who received
AWCs versus IV PCA throughout both time 1 (P 5
0.332) and time 2 (P 5 0.059). The AUPC was signifi-
cantly smaller for patients who received PCEA versus
AWC for both time 1 (P < 0.001) and time 2 (P 5
0.006). These findings were similar when the analysis
was conducted with the PSM data.
Oral Intake
The time to begin tolerating fluid sips postoperatively
was significantly longer in the AWC group (2.0 days,
SE 5 0.11 days) versus the IV PCA group (1.6 days,
SE 5 0.09 days; P 5 0.02) but was similar to the time
for the PCEA group (1.6 days, SE 5 0.14 days; Table 2).
In contrast, the AWC group advanced to a full diet ear-
lier than either the IV PCA group (3.5 versus 3.9 days;
TABLE 1. Demographics and Intraoperative Characteristics in the IV PCA, PCEA, and AWC Groups
Variable Group 1: IV PCA Group 2: PCEA Group 3: AWC
Age (years) 36.2 6 11.4 36.2 6 11.1 35.6 6 12.0
Sex (male/female) 81/86 28/40 40/44
BMI (kg/m2) 25.2 6 3.9 25.4 6 3.8 26.2 6 4.1
Intraoperative morphine equivalents
[mg; mean (SE)]
9.8 (0.6) 2.1 (0.4)* 8.6 (0.7)
Intraoperative fentanyl [lg; mean (SE)] 473.2 (16.0)* 311.3 (20.7) 350.0 (15.5)
Intraoperative dexamethasone [n (%)] 23 (13.8) 3 (4.4) 29 (34.5)†
Intraoperative ketamine [n (%)] 0 (0) 1 (1.5) 7 (8.3%)
Intraoperative fluid intake [mL; mean (SE)] 4592.2 (134.5) 4710.4 (202.4) 3360 (122.8)†
Estimated blood loss [mL; mean (SE)] 895.0 (52.9) 950.9 (83.0) 752.4 (103.3)
Length of procedure [minutes; mean (SE)] 364.1 (5.7) 361.5 (8.4) 350.1 (7.6)
Surgeon (A/B/C/D/E/F/G) 50/0/43/32/39/1/2 17/0/19/18/14/0/0 26/2/36/0/6/9/5
*P < 0.001 versus IV PCA and PCEA.
†P < 0.001 versus the AWC group.
Figure 1. Postoperative morphine-equivalent opioid consumption in the first 3 days after surgery in the IV PCA and AWC groups.
P 5 0.045) or the PCEA group (4.2 days; P 5 0.003).
Findings were similar with the PSM data.
Time to Ambulation
There was no difference in the time to ambulation
between the 3 groups in the unmatched data (Table 2)
and the propensity-matched data.
Length of Hospital Stay
There was no difference in the length of hospital stay
between the AWC group and the IV PCA group (P 5
0.071; Table 2). The length of hospital stay was signif-
icantly less for the AWC group (6.0 days, SE 5 0.12
days) versus the PCEA group (6.6 days, SE 5 0.22
days; P 5 0.028); however, this finding was nonsignifi-
cant with the PSM data (P 5 0.32).
Adverse Events
Eight patients (7.5%) in the AWC group were docu-
mented to have clinically important sedation (sedation
score  2) at some point during the first 3 postopera-
tive days. This was a significantly lower proportion
than that found in the IV PCA group (70.8%; P <
0.001) and the PCEA group (21.7%; P < 0.001).
Furthermore, those in the PCEA group had signifi-
cantly more pruritus than those in the AWC group
(P 5 0.004) and those in the IV PCA group (P 5
0.001). There was no difference in the incidence of
PONV between the 3 groups (Table 3). The findings
were similar with the PSM data.
DISCUSSION
Pain is a significant concern for patients undergoing
surgery.23 Severe postoperative pain negatively influ-
ences a patient’s satisfaction with his or her surgery
and anesthetic care.24 Furthermore, living liver donor
safety and satisfaction are important in order to
ensure the viability and longevity of adult donor pro-
grams. During the past 10 years, there has been a
reduction in the number of living liver donors.25
Postoperative pain is a disincentive and potentially a
factor contributing to this decline. It is important that
efforts are invested to improve care and reduce
Figure 2. Postoperative pain scores in the first 3 days after surgery in the IV PCA, PCEA, and AWC groups.
TABLE 2. Postoperative Recovery Milestones and Length of Hospital Stay for the IV PCA, PCEA, and AWC Groups
Variable
Group 1: IV PCA
[Mean (SE)]
Group 2: PCEA
[Mean (SE)]
Group 3: AWC
[Mean (SE)]
Time to fluid sips (days) 1.6 (0.09)* 1.6 (0.14) 2.0 (0.11)
Time to full diet (days) 3.9 (0.09)* 4.2 (0.21)* 3.5 (0.12)
Time to ambulation (days) 1.8 (0.09) 2.0 (0.15) 1.7 (0.13)
Length of hospital stay (days) 6.4 (0.13) 6.6 (0.22)* 6.0 (0.12)
*P < 0.001 versus the AWC group.
complications for those generous enough to donate
their organs.
There are 2 main strengths to our study. First, it
provides the largest investigation of catheters placed
along the TAP to date. Second, we have compared a
novel pain intervention to 2 standard-of-care modal-
ities: IV PCA and PCEA.
Findings from our study indicate that AWCs in liv-
ing liver donors provide an opioid-sparing effect in
comparison with patients using IV PCA alone after
postoperative day 2. There also appears to be an
interaction between opioid reduction and the time
after surgery. This interaction effect may be partially
explained by synergism between the natural history of
postoperative pain (ie, postoperative pain improves
with time) and the pain-reducing effect of AWCs. Pain
scores for patients receiving AWCs were similar to
those for patients receiving IV PCA and higher than
those for patients receiving epidural analgesia. At our
institution, we encourage patients to use their IV PCA
to keep their pain scores below 4/10 or within a level
of acceptable pain relief. Because patients in the AWC
group also received IV PCA, it is not surprising that
these 2 groups had similar pain scores. Although the
literature already indicates that epidural analgesia is
superior to IV PCA, our results suggest that epidural
analgesia is also superior to AWCs with back-up IV
PCA.
Despite epidural analgesia being considered the
gold standard for postoperative pain management
after open abdominal surgeries, it is used with cau-
tion in patients undergoing liver surgery.8,14 Patients
suffering from liver failure have significant reductions
in platelet numbers and changes in their coagulation
profile.10,11 Although living liver donors are relatively
healthy, the potential risk for catastrophic permanent
neurological complications to occur after a spinal or
epidural hematoma may have dissuaded the use of
epidural use in these patients. Moreover, local anes-
thetics and/or opioids delivered through epidural
infusions are associated with other adverse complica-
tions such as sedation, pruritus, urinary retention,
and arterial hypotension.8,26,27 Because of the risk-
to-benefit profile associated with epidural catheter
placement, AWCs may provide an option for patients
who are concerned about complications associated
with epidural analgesia or for whom epidurals are
contraindicated.
AWCs provide their analgesic effects by infusing
local anesthetics into the same anatomical space
where the nerves responsible for incisional postopera-
tive pain reside.28 Injecting or infusing local anes-
thetics into the TAP has gained popularity in recent
years. Initially described as a landmark technique to
be used after lower abdominal surgeries,29 variations
of the TAP block have been used in various open,
closed, upper, and lower abdominal surgeries.
Previous systematic reviews and meta-analyses on
perioperative TAP blocks suggest effective postopera-
tive pain control.15,30 However, only a few studies
have explored the use of TAP blocks or AWCs in liver
resection patients. Niraj et al.31 conducted a random-
ized controlled trial in liver and kidney surgical
patients comparing TAP catheters to epidural analge-
sia. They found that TAP catheters resulted in equiva-
lent pain scores on coughing at 8 and 72 hours
postoperatively. However, this study lacked an analy-
sis of side effects and hospital-based outcomes.
Although the results from a recent study by Behman
et al.21 suggest that surgically placed catheters in
liver resection patients can provide effective pain relief
after surgery, the study did not include a control
group, and this precludes a true estimate of their effi-
cacy. Nonetheless, these studies, in addition to our
investigation, provide an impetus for future prospec-
tive trials in this area.
Our study demonstrates that the opioid-sparing
effect of AWCs may result in a reduction in opioid-
related side effects. AWCs were associated with less
sedation than epidural analgesia and IV PCA alone.
The sedative effects of opioids are more pronounced
in those after liver resection because of transient
impairment of liver function and altered opioid metab-
olism; thus, any reduction in opioid consumption may
be clinically significant.32 It is also important to mini-
mize the sedative properties of narcotics after surgery
because these symptoms can be similar to those of
hepatic insufficiency, which may require urgent surgi-
cal intervention.6 Epidural analgesia was also associ-
ated with increased pruritus in this study. Increased
pruritus is a common side effect of epidural analgesia,
and it is believed to be due to the use of epidural
opioids.33-35 It should be noted that patients in this
study received hydromorphone in their epidural infu-
sions, which is known to cause pruritus and sedation.
Thus, an increase in pruritus and sedation in the
PCEA group in the study may be due to our institu-
tion’s use of epidural opioids. By avoiding opioids in
the epidural space and reducing parenteral opioid
consumption, AWCs provide an alternative for those
concerned about postoperative side effects.
There is emerging evidence that epidural analgesia
is associated with a decrease in postoperative
ileus.8,36 The biological mechanism of action is
believed to be due to a stimulant effect of systemically
absorbed local anesthetics on the gastrointestinal
TABLE 3. Postoperative Adverse Events Within the
First 3 Days After Surgery in the IV PCA, PCEA, and
AWC Groups
Variable
Group 1: IV
PCA [n (%)]
Group 2:
PCEA [n (%)]
Group 3:
AWC [n (%)]
Nausea 43 (25.7) 21 (30.9) 27 (32.1)
Vomiting 9 (5.4) 5 (7.4) 6 (7.1)
Pruritus 28 (16.8) 26 (38.2)* 14 (16.7)
Sedation 75 (44.9)† 23 (33.8)† 8 (9.5)
*P < 0.05 versus the AWC group.
†P < 0.001 versus the AWC group.
system.37 Because AWCs also use local anesthetics,
we examined their effect on surrogates of gastrointes-
tinal function (time to fluid and oral intake). Although
AWCs were associated with an increased time to fluid
sips, they were ultimately associated with a reduction
in the time to tolerate a full diet. To that extent that
systemic local anesthetic absorption in the AWC
group expedited gastrointestinal function, it is unclear
why advancement of diet was not shorter in the PCEA
group versus the IV PCA group (3.9 days with IV PCA
versus 4.2 days with PCEA). It is possible that the
prokinetic effect of systemically absorbed local anes-
thetics in the PCEA group may have been negated by
systemically absorbed opioids from the epidural solu-
tion.38 Nonetheless, reduced opioid-related side
effects and a decreased time to tolerate a full diet in
the AWC group possibly contributed to a reduced
length of hospital stay in comparison with the PCEA
group in the unmatched data. Reducing the time to
normal bowel function and the length of hospital stay
could have tremendous implications for hospital and
health care expenditures if these trends prove to be
consistent in large randomized controlled trials.
We believe that the surgical placement of AWCs has
several advantages. First, it enables active surgical
participation in the patient’s postoperative pain man-
agement. Second, it may allow improved placement of
catheters due to direct visualization. In the study of
Niraj et al.,31 a 63% success rate was achieved when
TAP catheters were placed under ultrasound guid-
ance. Our study obtained a 97% success rate, which
was similar to the study results of Behman et al.,21
who achieved a 94% success rate with the surgical
placement of catheters. Third, it prevents avoid
complications such as liver puncture or hematoma
formation associated with catheter placement via ana-
tomical landmarks or ultrasound guidance.39
Although our study suggests several benefits of
surgically placed AWCs after living liver donation,
there are several limitations to our investigation.
First, this study was a retrospective cohort study
and was vulnerable to several methodological issues,
such as recall bias and missing data. Second, this
study included patients from a 6-year period.
Although significant changes in perioperative man-
agement during this time period did not occur, slight
changes could have contributed to additional or
immeasurable confounding effects in this study.
Third, because this study sought to determine the
efficacy of AWCs, those with nonworking or partially
working catheters were excluded. Although this may
have introduced a selection bias, we believe that this
allowed a better assessment of the efficacy of the
analgesic technique. Finally, the propensity analysis
excluded patients who did not find a match in the
treatment group, and this reduced the statistical
power. Thus, differences such as postoperative day 3
opioid consumption and length of stay in the
unmatched data may have been significantly differ-
ent, but there was reduced statistical power to detect
an effect in the propensity analysis.
Findings from this study suggest several potential
benefits of AWCs, including a reduction in postopera-
tive opioid consumption, reduced adverse events, an
improved time to tolerate a full diet, and possibly a
decreased length of hospital stay. Although epidural
analgesia continues to provide the gold standard of
pain relief after surgery, AWCs appear to be a safe
adjunct to IV PCA after living liver donation. Future
prospective investigations on AWCs are needed before
their widespread and routine use can be advocated.
Large randomized controlled trials are needed to verify
potential benefits and determine safety and adverse
events associated with AWC use.
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